FOLH1 and prostate carcinoma: Hofman Hofman MS MS Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study Lancet Lancet 2020 2020 395 395 10231 10231 1208 1208 1216 1216 10.1016/S0140-6736(20)30314-7 10.1016/S0140-6736(20)30314-7 supplied-pmid 32209449?